AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed
Effects of B Cell Depletion Therapy on EBV-specific T-cells in Multiple Sclerosis
In an observational study of 183 participants, including 54 with MS receiving B cell depletion therapy (BCDT), results showed that BCDT is associated with lower frequencies of EBV-specific T-cells while maintaining T-cell functionality. Notably, patients treated with ofatumumab had higher EBV-specific CD8⁺ T-cell frequencies compared to those treated with ocrelizumab.
- Tags
- #ImmuneReset
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding the impact of BCDT on EBV-specific T-cell behavior is crucial for MS management, especially considering the role of EBV in disease progression.
What this does not prove
The specific effects of BCDT on EBV-specific immunity are not fully understood, especially compared to untreated MS patients and healthy controls.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 183 · basis not reported
- Randomised
- Not reported
- Controlled
- Yes
- Primary endpoint met
- Yes
- Relevant MS type
- All
- Publication date
- 2026-09-28
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Immune reset
Original sources
- Primary evidenceThe influence of anti-CD20-directed B cell depletion across different agents on Epstein-Barr virus-specific humoral and cellular immunity in patients with multiple sclerosis. ↗DOI: 10.1186/s12974-026-04062-0
Supporting passages (13)
study designIn this cross-sectional study, pwMS receiving BCDT, untreated pwMS at initial diagnosis (MS-ID), and age- and sex-matched HC were enrolled.
subjectsRESULTS: A total of 183 participants were included: 54 pwMS receiving BCDT (mean age 47.0±15.6 years; 31 females), 107 controls (47.2±18.3 years, 54 females), and 22 MS-ID (33.4±11.1 years, 20 females).
sample sizeRESULTS: A total of 183 participants were included: 54 pwMS receiving BCDT (mean age 47.0±15.6 years; 31 females), 107 controls (47.2±18.3 years, 54 females), and 22 MS-ID (33.4±11.1 years, 20 females).
controlledIn contrast, BCD-treated pwMS showed significantly lower frequencies of EBV-specific CD8⁺ (p<0.0001) and CD4⁺ T cells (p=0.0004) than controls, and lower EBV-specific CD8⁺ T-cell levels than MS-ID (p=0.0023).
primary endpoint metEBV-specific CD8⁺ T cells in both patients and controls were predominantly polyfunctional, coexpressing IFNγ, IL-2, and TNF.
research categoriesTitle: The influence of anti-CD20-directed B cell depletion across different agents on Epstein-Barr virus-specific humoral and cellular immunity in patients with multiple sclerosis.
relevant ms typesTitle: The influence of anti-CD20-directed B cell depletion across different agents on Epstein-Barr virus-specific humoral and cellular immunity in patients with multiple sclerosis.
interventionCONCLUSIONS: Unlike in treatment-naïve pwMS, BCDT is associated with selectively lower EBV-specific T-cell frequencies while EBV-specific and polyclonal T-cell functionality was largely preserved.
comparatorWhile EBV-specific T-cell responses may influence disease progression, the impact of anti-CD20 B-cell depletion therapy (BCDT) on EBV-specific cellular and humoral immunity remains insufficiently characterized, particularly in comparison with healthy controls (HC), untreated people with MS (pwMS), and pwMS on different BCDT agents.
primary endpointEBV-specific and polyclonal CD8+ and CD4⁺ T-cell responses were quantified and functionally characterized following stimulation with a EBV-derived peptide-mix predominately containing MHC class I binding peptides or Staphylococcus aureus enterotoxin B (SEB) using multiparametric flow cytometry.
findingsIn contrast, EBV-specific antibody levels were persistently higher despite treatment.
limitationsWhile EBV-specific T-cell responses may influence disease progression, the impact of anti-CD20 B-cell depletion therapy (BCDT) on EBV-specific cellular and humoral immunity remains insufficiently characterized, particularly in comparison with healthy controls (HC), untreated people with MS (pwMS), and pwMS on different BCDT agents.
publication datePublication date: 2026-09-28
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.